Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
Background and study Aims: Liver cancer, most commonly known as hepatocellular carcinoma (HCC), was ranked as the sixth most common cancer in Saudi Arabia in 2014. Management of unresectable HCC is multidisciplinary and could include radiofrequency ablation, systemic-targeted therapy, and transarter...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Journal of Nature and Science of Medicine |
Subjects: | |
Online Access: | http://www.jnsmonline.org/article.asp?issn=2589-627X;year=2020;volume=3;issue=2;spage=115;epage=120;aulast=Helmi |
id |
doaj-2e8673960f674429bfe200f0b2e35907 |
---|---|
record_format |
Article |
spelling |
doaj-2e8673960f674429bfe200f0b2e359072020-11-25T04:01:59ZengWolters Kluwer Medknow PublicationsJournal of Nature and Science of Medicine2589-627X2589-62882020-01-013211512010.4103/JNSM.JNSM_30_19Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinomaHadeel A HelmiFalwah F AlharthiAhmad A MadkhaliFaisal A AlsaifAlbatoul Y AlshanifiWeam S HusseinShargan M BinKhamisAbdulsalam AlsharabiMazen M HassanainBackground and study Aims: Liver cancer, most commonly known as hepatocellular carcinoma (HCC), was ranked as the sixth most common cancer in Saudi Arabia in 2014. Management of unresectable HCC is multidisciplinary and could include radiofrequency ablation, systemic-targeted therapy, and transarterial chemoembolization (TACE). This study aimed to assess the survival outcome of patients with unresectable HCC undergoing TACE in Saudi Arabia. Patients and Methods: We retrospectively studied patients with unresectable HCC who were treated with TACE between 2004 and 2016. Patient's demographics, etiology of liver disease, Child–Turcotte–Pugh stage, computed tomography scan findings, laboratory results, details of treatment sessions, and follow-up visit data were obtained from the National Liver Disease Research Database. Results: Thirty-nine patients diagnosed with HCC underwent 103 TACE sessions at our hospital. Median overall survival time was 20 months (range 0–98). Median progression-free survival was 9 months (range 1–98). Follow-up imaging revealed progressive disease in 20 patients (54.05%), while 17 had no disease progression, and none had complete resolution. Conclusion: Our results are similar to those of previous studies that reported the benefit of TACE on survival rates of HCC patients. The correlation found between median overall survival and international normalized ratio and bilirubin level could reflect the importance of liver function deterioration effects on outcomes.http://www.jnsmonline.org/article.asp?issn=2589-627X;year=2020;volume=3;issue=2;spage=115;epage=120;aulast=Helmihepatocellular carcinomaliver diseasesaudi arabiasurvivaltransarterial chemoembolization |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hadeel A Helmi Falwah F Alharthi Ahmad A Madkhali Faisal A Alsaif Albatoul Y Alshanifi Weam S Hussein Shargan M BinKhamis Abdulsalam Alsharabi Mazen M Hassanain |
spellingShingle |
Hadeel A Helmi Falwah F Alharthi Ahmad A Madkhali Faisal A Alsaif Albatoul Y Alshanifi Weam S Hussein Shargan M BinKhamis Abdulsalam Alsharabi Mazen M Hassanain Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma Journal of Nature and Science of Medicine hepatocellular carcinoma liver disease saudi arabia survival transarterial chemoembolization |
author_facet |
Hadeel A Helmi Falwah F Alharthi Ahmad A Madkhali Faisal A Alsaif Albatoul Y Alshanifi Weam S Hussein Shargan M BinKhamis Abdulsalam Alsharabi Mazen M Hassanain |
author_sort |
Hadeel A Helmi |
title |
Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma |
title_short |
Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma |
title_full |
Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma |
title_fullStr |
Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma |
title_full_unstemmed |
Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma |
title_sort |
outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma |
publisher |
Wolters Kluwer Medknow Publications |
series |
Journal of Nature and Science of Medicine |
issn |
2589-627X 2589-6288 |
publishDate |
2020-01-01 |
description |
Background and study Aims: Liver cancer, most commonly known as hepatocellular carcinoma (HCC), was ranked as the sixth most common cancer in Saudi Arabia in 2014. Management of unresectable HCC is multidisciplinary and could include radiofrequency ablation, systemic-targeted therapy, and transarterial chemoembolization (TACE). This study aimed to assess the survival outcome of patients with unresectable HCC undergoing TACE in Saudi Arabia. Patients and Methods: We retrospectively studied patients with unresectable HCC who were treated with TACE between 2004 and 2016. Patient's demographics, etiology of liver disease, Child–Turcotte–Pugh stage, computed tomography scan findings, laboratory results, details of treatment sessions, and follow-up visit data were obtained from the National Liver Disease Research Database. Results: Thirty-nine patients diagnosed with HCC underwent 103 TACE sessions at our hospital. Median overall survival time was 20 months (range 0–98). Median progression-free survival was 9 months (range 1–98). Follow-up imaging revealed progressive disease in 20 patients (54.05%), while 17 had no disease progression, and none had complete resolution. Conclusion: Our results are similar to those of previous studies that reported the benefit of TACE on survival rates of HCC patients. The correlation found between median overall survival and international normalized ratio and bilirubin level could reflect the importance of liver function deterioration effects on outcomes. |
topic |
hepatocellular carcinoma liver disease saudi arabia survival transarterial chemoembolization |
url |
http://www.jnsmonline.org/article.asp?issn=2589-627X;year=2020;volume=3;issue=2;spage=115;epage=120;aulast=Helmi |
work_keys_str_mv |
AT hadeelahelmi outcomeoftransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT falwahfalharthi outcomeoftransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT ahmadamadkhali outcomeoftransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT faisalaalsaif outcomeoftransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT albatoulyalshanifi outcomeoftransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT weamshussein outcomeoftransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT sharganmbinkhamis outcomeoftransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT abdulsalamalsharabi outcomeoftransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma AT mazenmhassanain outcomeoftransarterialchemoembolizationinpatientswithunresectablehepatocellularcarcinoma |
_version_ |
1724444822944612352 |